# Usana Health Sciences Inc.

**USNA**

NYSE; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0000896264

**B**

**second fifth of 369 graded peers in healthcare**

rank 118 of 369; percentile 31.8; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**



## Scoreboard

| | |
|---|---|
| **Profitability** | B<br>percentile 32.4 |
| **Solvency** | B/C<br>percentile 40.6 |
| **Growth and financing** | C<br>percentile 55.6 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $742.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 10 of 14 |
| **Graded from** | filings received through Mar 16, 2026<br>241 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026 |
| **Last close** | $12.93<br>2026-11-11; market equity $238.8M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 16, 2026*

," and Part II, "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, as well as in the other filings we make from time to time with the SEC, in evaluating us, our business and an investment in our securities. Below is a summary of the principal factors that make an investment in the common stock of the Company risky or speculative. This summary does not address all of the risks we face. Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," and "USANA" refer to USANA Health Sciences, Inc. and its wholly owned subsidiaries.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 32.4** | | | | | | |
| Gross profitability | 97.5% | 32.3% | | 3.6 | 365 | 2026-01-03 |
| Return on invested capital | not computable | 9.3% | | | | |

*one or more required annual facts are missing*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (1.6%) | (6.6%) | 77.9 | 801 | 2026-01-03 |
| Gross margin stability, five years | 1.2 pts | 2.8 pts | 15.8 | 242 | 2026-01-03 |
| **Solvency, sleeve percentile 40.6** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 7.37 | (0.35) | 13.3 | 745 | 2026-01-03 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-30; latest annual assets end 2026-01-03* | | | | | |
| Current ratio | 2.24x | 2.95x | 67.8 | 827 | 2026-01-03 |
| **Growth and financing, sleeve percentile 55.6** | | | | | |
| Revenue growth, three-year compound | (2.5%) | 10.1% | 77.4 | 412 | 2026-01-03 |
| Free cash flow growth, three-year compound | (55.0%) | 11.0% | 97.9 | 95 | 2026-01-03 |
| Reinvestment rate | 14.9% | 37.1% | 60.6 | 105 | 2026-01-03 |
| Asset growth, three years | 7.6% | 2.2% | 35.7 | 695 | 2026-01-03 |
| Net share issuance, one year | (2.4%) | 2.5% | 6.4 | 628 | 2026-03-13 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 113 | Verastem, Inc. (VSTM) | 30.4 | B | dilution, fortress balance sheet |
| 114 | BioNexus Gene Lab Corp. (BGLC) | 30.7 | B | dilution, late filer |
| 115 | Arcutis Biotherapeutics, Inc. (ARQT) | 31.0 | B | |
| 116 | Insmed Inc. (INSM) | 31.2 | B | |
| 117 | Stryker Corp. (SYK) | 31.5 | B | |
| 118 | Usana Health Sciences Inc. (USNA) | 31.8 | B | |
| 119 | Avalo Therapeutics, Inc. (AVTX) | 32.1 | B | dilution, degenerate inputs |
| 120 | Collegium Pharmaceutical, Inc. (COLL) | 32.3 | B | fortress balance sheet |
| 121 | Eton Pharmaceuticals, Inc. (ETON) | 32.6 | B | |
| 122 | Koru Medical Systems, Inc. (KRMD) | 32.9 | B | fortress balance sheet |
| 123 | CVRx, Inc. (CVRX) | 33.2 | B | |

## What the price implies

*at the 2026-11-11 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (31.6%) | (1.9%) | 29 |
| Distance from 52-week high | (44.7%) | (27.8%) | 33 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | 3.6% | (1.0%) | 73 |
| Book value to price | 2.22 | 0.27 | 96 |
| Sales to price | 3.90 | 0.29 | 97 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | (12.1%) | 20.8% | 14 |
| Relative strength against the sector, log excess return | (0.55) | (0.19) | 29 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-01-03** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $168.6M |
| Operating cash flow, four quarters | $27.7M |
| Months of runway | not finite |
| Days since last periodic filing | 91 (10-Q received Aug 13, 2026) |
| Median daily dollar volume, 63 sessions | $2.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $724.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 2 | assets | us-gaap:Assets | $742.9M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 3 | net income | us-gaap:NetIncomeLoss | $10.8M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $22.3M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 5 | assets | us-gaap:Assets | $748.2M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $925.3M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 7 | gross profit | us-gaap:GrossProfit | $693.3M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $854.5M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 9 | gross profit | us-gaap:GrossProfit | $744.3M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $921.0M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 11 | gross profit | us-gaap:GrossProfit | $804.7M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $998.6M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 13 | gross profit | us-gaap:GrossProfit | $968.6M | 2022-01-01 | 2024-02-27 | 10-K | 24-000093 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.2B | 2022-01-01 | 2024-02-27 | 10-K | 24-000093 |
| 15 | current assets | us-gaap:AssetsCurrent | $288.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $128.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $465.7M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $37.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 19 | book equity | us-gaap:StockholdersEquity | $533.1M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 20 | liabilities | us-gaap:Liabilities | $156.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | $93.1M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 22 | interest expense | us-gaap:InterestExpense | $262,000 | 2023-12-30 | 2024-02-27 | 10-K | 24-000093 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $13.8M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $61.0M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.1M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $70.6M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $14.5M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $103.9M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.4M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 30 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $32.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $41.5M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $30.1M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 33 | current assets | us-gaap:AssetsCurrent | $279.2M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $139.6M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 35 | assets | us-gaap:Assets | $632.8M | 2023-12-30 | 2025-03-12 | 10-K | 25-000092 |
| 36 | assets | us-gaap:Assets | $596.5M | 2022-12-31 | 2024-02-27 | 10-K | 24-000093 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 18,456,935 | 2026-03-13 | 2026-03-16 | 10-K | 26-000021 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 18,904,526 | 2025-03-07 | 2025-03-12 | 10-K | 25-000092 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.